SOX2 and esophageal squamous cell carcinoma: Decursin demonstrated potent antitumor activity against ESCC by inducing cell cycle deceleration, apoptosis, and ubiquitin–proteasome-mediated degradation of oncoproteins TP63 and SOX2.